Update: Registration for Creative Biolabs’ Webinar About ConvertibleCAR-T Is Now Opened

by Bella Smith Contributor

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   481    Comments 0

Recognized as the leading custom service provider with extensive experience in TCR and CAR-T&NK cell immune therapy development, Creative Biolabs has invited Dr. Eytan Herzig to share his experimental results about convertibleCAR-T platform in HIV cure.

With the exponentially increased demand in modern novel medicine, CAR-T immunotherapy has been one of the most promising approaches for target-specific cancer treatment. And now, it has extended its application to HIV cure.

Acquired Immunodeficiency Syndrome (AIDS) is an infectious disease caused by infection with HIV virus, which attack human body's immune system. It takes CD4 T lymphocytes, an important part in immune system, as the main target of attack, destroying the cells in large quantities. Then, the human body is susceptible to various diseases, and malignant tumors can also occur with a high fatality rate.

Scientists have been exploring the treatment of HIV infection for years and recently, the latest research of Dr. Eytan Herzig, a Staff Research Scientist in the Gladstone Center for HIV Cure Research, shows that the convertibleCAR-T cells can detect and eliminate HIV-infected cells. By reducing the size of the HIV reservoir and engineering an immune response that can effectively control the shrunken reservoir in the absence of antiretroviral therapy, this treatment may be the next super player in HIV cure.

To further promote the discovery of HIV treatment and move forward the research and development of CAR-T therapy, Creative Biolabs has invited Dr. Eytan Herzig to share his latest research on the innovative convertibleCAR-T platform in an upcoming webinar.

Basic information of the Webinar:

Subject: ConvertibleCAR-T, a highly adaptable CAR-T platform to fight HIV

Time: 3:00 p.m. EDT/12:00 p.m. PDT (June 4th, 2020)

Charge: Free


  • The potential approach to achieving a functional HIV cure
  • The process of convertibleCAR-T’s detecting and eliminating HIV infected cells
  • The performance of the convertibleCAR-T cells ex vivo and in vivo
  • ConvertibleCAR-T cells’ advantages over conventional CAR-T cells

Creative Biolabs is a world-renowned service provider for immunotherapy. With one of the world’s largest collection of CAR products of different generations targeting various biomarkers, it continues to innovate the next generation CAR technologies to achieve even greater results. With integrated global resources in all aspects, Creative Biolabs provides one-stop full CAR T/NK Cell therapy development service, including early non-clinical research, process development, pre-clinical animal model testing, cGMP manufacturing, and phase I-III clinical trials.

The webinar registration is now opened and Creative Biolabs, together with Dr. Eytan Herzig, gives warm welcomes to all participants and will be delighted to answer any related questions during the webinar. Further information can be reached at https://www.creative-biolabs.com/car-t/.


About Creative Biolabs

As a global company, Creative Biolabs has talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, Creative Biolabs is the established leading expert in TCR and CAR T&NK cell immune therapy development, offering the one-stop custom services that cover the entire new drug development pipeline.

Subscribe to Newsletter
Share this:              


There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *